Menu Search
Equities

Gilead Sciences Inc

GILD:SGO

Gilead Sciences Inc

Actions
  • Price (USD)65.55
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of May 06 2021.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Gilead Sciences Inc's net income fell -26.23% from 6.23bn to 4.59bn despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 19.21% to 20.79%.
Gross margin79.17%
Net profit margin20.48%
Operating margin32.68%
Return on assets8.86%
Return on equity27.28%
Return on investment10.45%
More ▼

Cash flow in USDView more

In 2022, Gilead Sciences Inc did not generate a significant amount of cash. However, the company earned 9.07bn from its operations for a Cash Flow Margin of 33.25%. In addition the company used 2.47bn on investing activities and also paid 6.47bn in financing cash flows.
Cash flow per share6.19
Price/Cash flow per share12.31
Book value per share16.82
Tangible book value per share-12.55
More ▼

Balance sheet in USDView more

Gilead Sciences Inc has a Debt to Total Capital ratio of 54.66%, a lower figure than the previous year's 126.38%.
Current ratio1.28
Quick ratio1.13
Total debt/total equity1.20
Total debt/total capital0.5466
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)3.90%
Div growth rate (5 year)7.02%
Payout ratio (TTM)67.17%
EPS growth(5 years)-13.86
EPS (TTM) vs
TTM 1 year ago		23.59
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.